The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | ASPIRE trial for MM: updates from ASH 2017
The ongoing Phase III ASPIRE trial (NCT01080391) comparing carfilzomib, lenalidomide and dexamethasone (CRd) vs. lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (MM) has been producing promising results thus far. In this interview, Keith Stewart, MD, ChB, of the Mayo Clinic, Scottsdale, AZ, discusses the updates on the trial that were presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. These included updates on progression-free survival, as well as results for overall survival that were presented for the first time.
